PSMA Ligand Solid-Phase Synthesis for Efficient, High-Purity Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for cost-effective synthesis methods that can deliver high-purity quantities of urea-based prostate specific membrane antigen (PSMA) ligands for the treatment of prostate cancer, particularly for endo-radiotherapy, as existing methods are inefficient and costly.
Innovation Solution
A method for synthesizing PSMA ligands using solid phase synthesis, involving a series of steps with resin-based compounds and specific protecting groups, linkers, and chelating agents like DOTA, which allows for efficient and cost-effective production with yields greater than 10%.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional synthesis methods are used for urea-based PSMA ligands, then the synthesis can be performed with existing procedures, but the production is inefficient and costly with low yields
Solution Approach 1:
The patent changes the synthesis parameters by using solid-phase peptide synthesis (SPPS) methodology with specific protecting groups (Fmoc, Boc) and coupling reagents (HATU, HCTU, HOBT). This approach transforms the synthesis from conventional solution-phase to solid-phase, enabling automated synthesis and improving both efficiency and yield while reducing costs through standardized protocols
Solution Approach 2:
The patent introduces resin-based intermediates as solid supports for stepwise assembly of the PSMA ligand. The resin acts as an intermediary carrier that facilitates repeated coupling and deprotection cycles, enabling efficient building block assembly and simplifying purification steps, which directly addresses the productivity and cost issues
2Manufacturing precision
If conventional synthesis methods are used, then existing procedures can be followed, but the product purity is insufficient for clinical applications
Solution Approach 1:
The patent extracts the growing peptide chain from solution phase and anchors it to solid resin support. This separation allows for easy removal of excess reagents and byproducts through filtration, dramatically improving product purity. The solid-phase methodology enables repeated washing steps that effectively remove impurities while maintaining the desired compound on the resin
Solution Approach 2:
The patent employs preliminary protection of functional groups (carboxyl groups with Boc or Fmoc, amine groups with appropriate protecting groups) before assembly. This preliminary action prevents unwanted side reactions during synthesis and ensures high purity of the final product by controlling the reactivity of each functional group at the appropriate synthesis stage
Data Source
Figure 1
AI summary
The present disclosure relates to the synthesis of prostate specific membrane antigen (PSMA) ligands that are useful in the treatment of diseases like cancer. In particular, the disclosure relates to a method for synthesizing PSMA ligands having a glutamate-urea-lysine (GUL) moiety and a chelating agent that can comprise a radiometal.